Lisanti Capital Growth LLC Trims Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Lisanti Capital Growth LLC lessened its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 42.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,740 shares of the medical equipment provider's stock after selling 33,135 shares during the period. Lantheus accounts for approximately 1.2% of Lisanti Capital Growth LLC's investment portfolio, making the stock its 27th largest holding. Lisanti Capital Growth LLC owned about 0.06% of Lantheus worth $4,910,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Lantheus by 2.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 31,629 shares of the medical equipment provider's stock worth $1,969,000 after buying an additional 741 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Lantheus by 10.0% in the first quarter. Janney Montgomery Scott LLC now owns 8,804 shares of the medical equipment provider's stock worth $548,000 after acquiring an additional 799 shares during the period. Texas Permanent School Fund Corp raised its stake in shares of Lantheus by 1.2% during the 1st quarter. Texas Permanent School Fund Corp now owns 59,876 shares of the medical equipment provider's stock valued at $3,727,000 after buying an additional 711 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its position in Lantheus by 9.0% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 5,369 shares of the medical equipment provider's stock valued at $334,000 after acquiring an additional 442 shares in the last quarter. Finally, Empowered Funds LLC purchased a new stake in Lantheus during the first quarter worth $2,358,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on LNTH. JMP Securities decreased their target price on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research report on Thursday. B. Riley lifted their price objective on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Redburn Atlantic started coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price on the stock. Truist Financial reiterated a "buy" rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday. Finally, StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Friday. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $122.50.

Lantheus Stock Down 3.9 %

LNTH stock traded down $3.42 during mid-day trading on Monday, hitting $84.08. 2,334,730 shares of the company were exchanged, compared to its average volume of 997,277. The business has a fifty day simple moving average of $107.33 and a 200-day simple moving average of $96.12. The firm has a market capitalization of $5.85 billion, a P/E ratio of 14.56 and a beta of 0.51. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.